论文部分内容阅读
目的观察卡维地洛治疗慢性心力衰竭的临床疗效及安全性。方法将58例CHF患者随机分为卡维地洛组与美托洛尔组,每组各29例。记录两组治疗前后HR、LVEF、LVDEd及LVESd,进行统计学比较分析。结果经以上治疗后,卡维地洛组29例中显效11例,有效17例,无效1例,总有效率96.6%;美托洛尔组29例中显效8例,有效18例,无效3例,总有效率89.7%。两组总有效率比较,P<0.05,差异有统计学意义。结论卡维地洛可明显改善CHF患者的心功能,其远期疗效优于美托洛尔。
Objective To observe the clinical efficacy and safety of carvedilol in the treatment of chronic heart failure. Methods 58 patients with CHF were randomly divided into carvedilol group and metoprolol group, 29 cases in each group. The two groups were recorded before and after treatment HR, LVEF, LVDEd and LVESd, statistical analysis. Results After the above treatment, in 29 cases of carvedilol group, 11 cases were markedly effective, 17 cases were effective and 1 case was ineffective, with a total effective rate of 96.6%. In 29 cases of metoprolol group, 8 cases were markedly effective, 18 cases were effective and 3 was ineffective For example, the total effective rate of 89.7%. The total effective rate between the two groups, P <0.05, the difference was statistically significant. Conclusion Carvedilol can significantly improve cardiac function in patients with CHF, its long-term efficacy is superior to metoprolol.